Skip to content

Industry News

Nexxus Capital Announces Investment in IMMUNOTEC

22 March 2017

Nexxus Capital signed an agreement to invest in Immuno Holding, a company focused on the development and commercialization of nutritional supplements via multilevel direct sales channels.

(Press Release) Nexxus Capital announces that on March 22, 2017 it has signed the agreements to realize an investment in Immuno Holding, S.A. de C.V., a company that, through its subsidiaries after closing of the transaction (“IMMUNOTEC”), is focused on the development and commercialization of nutritional supplements through multi-level direct sales channels.

The investment will be realized in association with Mauricio Domenzain, who has ample industry experience in Mexico, the United States and other countries, as a former executive of a prominent direct selling company.

The management team that has driven IMMUNOTEC’s success will continue under the direction of Mauricio Domenzain.

The investment will be carried out by Nexxus VI (Nexus Capital Private Equity Fund VI, L.P. and Nexxus Capital VI Trust (NEXX6CK 13)), subject to certain approvals and closing conditions.

IMMUNOTEC is a company with over 20 years of leadership. Its products are commercialized through multilevel direct sales channels mainly in Mexico, with presence in other countries, including the United States and Canada. Among the broad product portfolio that IMMUNOTEC offers is the Immunocal family of products, which has brought health benefits to consumers for over 20 years.

According to the World Federation of Direct Selling Associations, the nutritional supplements category has become the category with the largest size and growth in the global direct sales industry.